Atea Pharmaceuticals, Inc. (AVIR) NASDAQ

Currency In USD

Atea Pharmaceuticals, Inc.

Address

225 Franklin Street

Boston, MA 02110

United States of America (the)

Phone

857 284 8891

Website

https://www.ateapharma.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

October 30, 2020

Key Executives

Name	Title	Pay	Year Born
Jean-Pierre Sommadossi	Founder, Chairman, Chief Executive Officer & President	1.13M	1956
Wayne Foster	Executive Vice President of Finance & Chief Accounting Officer	580,463	1969
John F. Vavricka	Chief Commercial Officer	634,437	1963
Maria Arantxa Horga	Chief Medical Officer	747,102	1968
Andrea J. Corcoran	Chief Financial Officer, Executive Vice President of Legal & Secretary	810,818	1962
Janet J. Hammond	Chief Development Officer	870,794	1960
Xiao-Jian Zhou	Executive Vice President of Early Stage Development	0	N/A
Keith Pietropaolo	Executive Vice President of Clinical Sciences & Project Management	0	N/A
Jonae R. Barnes	Senior Vice President of Investor Relations & Corporate Communications	0	N/A
Laura Ishak	Senior Vice President of Clinical Operations	0	N/A
Qi Huang	Senior Vice President of Virology	0	N/A
Adel Moussa	Executive Vice President of Chemistry	0	N/A
Jayanthi Wolf	Executive Vice President of Regulatory Affairs	0	N/A
Nancy Gail Berry Agrawal	Executive Vice President of Preclinical Development	0	N/A

Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.